PreveCeutical Medical Inc.
PreveCeutical Medical Inc.
- ISIN: CA74141E1043
- Land: .
Nachricht vom 23.01.2020 | 14:00
PreveCeutical Retains Patent Legal Team
DGAP-News: PreveCeutical Medical Inc.
/ Key word(s): Miscellaneous
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") has retained Griffith Hack as their patent attorneys.
Following the successful completion of our novel designed peptides derived from Caribbean blue scorpion venom and with our two other programs coming to a close during 2020, we will need to ensure all our intellectual property is patented in order to protect its value. PreveCeutical has retained Griffith Hack to ensure intellectual property is secure.
Griffith Hack assist clients not only with procuring IP but also with its IP strategy. They have attorneys qualified in fields such as chemistry, physics, and biotechnology. We will be working closely with Dr. Kathryn Morris, a Principal and Patent Attorney at Griffith Hack. Dr. Morris has designations in Organic Chemistry and Intellectual Property Law. PreveCeutical will be working with Griffith Hack to create the best value from the IP created by our current four research and development programs with UniQuest and the University of Queensland, Australia.
"These patent filings are critical to PreveCeutical as we are now currently working to discuss potential of partnering with biotech and pharmaceutical companies to further the application of technologies for "out licensing" towards achieving targeted drug delivery for their active new chemical entities ", stated Dr. Mak Jawadekar.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the soluble gel drug delivery research and development program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
About Griffith Hack
Griffith Hack knows IP and the importance of protecting it, which they do with smarter IP development, performance tracking and management, which they call IP amplified.
Griffith Hack is proudly recognized as a Leading Firm for Intellectual Property in the Chambers and Partners 2020 Asia-Pacific legal guide.
For more information about Giffith Hack, please visit https://www.griffithhack.com.
On Behalf of the Board of Directors of PreveCeutical
"Dr. Makarand (Mak) Jawadekar"
For further information, please contact:
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the applying for any patent(s), being granted any patent(s), and the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, and that PreveCeutical will be able to obtain the financing required to carry out its planned future activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities including the acceptance of any patent appplications and the granting of the patents thereunder; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities; and the ability of PreveCeutical to commercialise products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedar.com. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
This news release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the Canada, United States, or any other jursidiction. The securities of the Company have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/51765
Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/51765
News Source: Newsfile
|Company:||PreveCeutical Medical Inc.|
|EQS News ID:||959961|
|End of News||DGAP News Service|
Event im Fokus
14.-15.10.2020 Fachkonferenzen Finanzdienstleistungen und Technologie
11.-12.11.2020 Fachkonferenzen Software/IT und Branchenmix
Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen könnten die Fachkonferenzen im Herbst/Winter ggf. auch virtuell stattfinden.
Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet
Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.
Der AKTIONÄR News
26. Oktober 20:13 Schlussglocke: US-Märkte schwach – Investoren verängstigt durch ...
26. Oktober 20:09 Tesla greift weiter an – die 12 Milliarden-Dollar-Überraschung
26. Oktober 19:11 Zoom-Aktie stark gegen den Strom – Kursplus, aber warum?
26. Oktober 18:40 Dow rauscht unter Marke von 28.000 – Stimmung bleibt gedrückt
26. Oktober 16:40 Ballard Power und Plug Power: Diese Marken sind entscheidend
News im Fokus
Linde plc: Linde Appoints Sanjiv Lamba as Chief Operating Officer
26. Oktober 2020, 18:37
Q3 2020 Results Webcast
03. November 2020
Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Kaufen Valneva SE
26. Oktober 2020